Infinity Pharmaceuticals Inc. (INFI): Billionaire Steve Cohen’ SAC Up to 5% of This Stock

Page 1 of 2

According to a 13G filed with the SEC, SAC Capital Advisors, a hedge fund managed by billionaire Steve Cohen, owned 2.4 million shares of Infinity Pharmaceuticals Inc. (NASDAQ:INFI), giving the fund 5% of the total shares outstanding of the $1.9 billion market cap biotechnology company. We track SAC’s quarterly 13F filings alongside those of many other hedge funds and notable investors as part of our work developing investment strategies (we have found, for example that the most popular small cap stocks among hedge funds generate an average excess return of 18 percentage points per year), and so we can see that the fund and its Sigma subsidiary together had owned about 210,000 shares at the beginning of January (find Cohen’s favorite stocks). Infinity Pharmaceuticals Inc. (NASDAQ:INFI) is working on drug development and placing its products in clinical trials, including for patients with arthritis and asthma.

Looking at our database of filings, Samuel Isaly’s Orbimed Advisors, which focuses on healthcare investments, increased the size of its position in Infinity by 68% during the fourth quarter of 2012 to a total of 3.2 million shares (see Isaly’s stock picks). Perceptive Advisors, a biotechnology focused hedge funds managed by Joseph Edelman, cut its stake slightly but still closed December with 2.5 million shares in its portfolio (check out more stocks Perceptive owns). We would note that two major institutional shareholders which had owned over 10% of the company recently reported dumping their shares; these transactions were reported as insider sales (research insider sales at Infinity).

Steven CohenInfinity Pharmaceuticals Inc. (NASDAQ:INFI)’s stock price had been doing quite well, having been up 35% year to date as of the beginning of April before plunging this month (likely due to these share sales). It is now up only 5% for 2012, but over 200% in the last year. As a development stage company, it only receives revenue in the form of collaborative research and development funds, a figure which declined last year compared to 2011. Almost $120 million was used on research and development for the year, which made up the overwhelming majority of Infinity Pharmaceuticals Inc. (NASDAQ:INFI)’s expenses. The company used $80 million in cash on operations in 2012, raising cash from the issuance of common stock. At the end of the year, Infinity had $180 million in cash and cash equivalents as well as $150 million in liquid securities, which should be sufficient to cover operations for at least some time. Analysts are not expecting the company to be profitable this year or next year.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 44 percentage points in 21 months Learn how!

Lists

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

12 Most Expensive Countries for Foreign Students

Top 30 Most Influential Women in the World

Top 20 Most Expensive New Year Eve Shows

Top 5 Best Vocational Careers

Top 10 Jobs for 2014 by Salary Gain (Predictions)

Top 5 Digital Trends for 2014

Top 6 Things You Can Do To Increase Your Productivity

Top 9 Trending Smartphones in 2013

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!